A novel NFkB1 mutation linking pyoderma gangrenosum and common variable immunodeficiency

Qisi Sun, MD, a,b Jeff R. Gehlhausen, MD, PhD, a Marianna Freudzon, MD, a Nour Kibbi, MD, c Allen Bale, MD, d Keith Choate, MD, PhD, a Mary Tomayko, MD, PhD, a Ian Odell, MD, PhD, a and Sarika Ramachandran, MD a

New Haven, Connecticut; Boston, Massachusetts; Stanford, California

Key words: dermatoses; genetics; immunodeficiency; inflammatory; neutrophilic; pyoderma gangrenosum; ulcers.

INTRODUCTION

Pyoderma gangrenosum (PG) is a sterile neutrophilic dermatosis manifesting as painful inflammatory plaques and ulcers, frequently associated with inflammatory bowel disease, rheumatoid arthritis, myelodysplastic syndrome, and acute myeloid leukemia. 1 We present a case of a young woman with a novel mutation in NFkB1 who experienced common variable immunodeficiency (CVID) and severe recurrent PG episodes.

CASE REPORT

A 24-year-old woman with CVID treated with intravenous immunoglobulin presented with fever, leukocytosis, and painful dehiscence of incision sites following laparoscopic cholecystectomy. Across her abdomen were 5 deep ulcers with violaceous undermined borders (Fig 1). Histopathology revealed dense neutrophilic infiltrates, and cultures for bacteria, fungi, and acid-fast bacilli were negative, altogether consistent with a diagnosis of PG. Treatment with prednisone 1 mg/kg/day resulted in clinical improvement, but after 1 week, the patient developed posterior reversible encephalopathy syndrome. Prednisone was discontinued, and infliximab 5 mg/kg every 8 weeks was started, leading to resolution of lesions by the fourth infusion. Given her presentation of severe PG at a young age with coexisting immunodeficiency, exome sequencing was completed, which revealed a likely pathogenic variant in NFkB1 (C.A2415G, p.Q805Q), which she shared with her unaffected father.

Years later, she was in a motor vehicle accident resulting in a left scaphoid fracture, and she developed a 30-cm undermined ulcer on the lower abdomen with purulent drainage (Fig 1). Biopsy again showed PG. Prednisone 50 mg (0.5 mg/kg), infliximab 500 mg (5 mg/kg), and 0.05% clobetasol resulted in abdominal ulcer resolution; however, infliximab treatment was complicated by debilitating arthralgias. The patient’s third episode of PG occurred after surgical repair of her scaphoid fracture. She developed fever, pain, and a purulent ulcer at the site of the surgical wound consistent with PG (Fig 2). Biopsy was deferred in the setting of PG history and pathergy risk. She was managed with a brief course of cyclosporine (5 mg/kg) twice a day with lower-dose prednisone 0.2 mg/kg/day, resulting in full healing of the surgical site.

DISCUSSION

The pathophysiology of PG is poorly understood, but increasing evidence supports the role of genetics...
in PG pathogenesis. Most commonly associated with 
\textit{PSTPIP1}, \textit{MTHFR}, and \textit{JAK2} mutations, PG typically 
presents in middle-aged women and rarely co-
occurs with immunodeficiency.\textsuperscript{1-4}

We describe a young woman in her early 20s with 
CVID and PG linked to a novel, heterozygous \textit{NFkB1} 
variant. \textit{NFkB1} in the nuclear-factor kappa B (NF-\kappa B) 
pathway encodes the p105 protein, which is processed 
to generate the p50 transcription factor that then 
activates the NF-\kappa B cascade central to immune func-
tion.\textsuperscript{5} \textit{NFkB1} mutations are known to cause CVID, 
primarily through a loss of function of the p50 
subunit.\textsuperscript{3} Studies demonstrate that the absence of a 
properly functioning NF-\kappa B protein disrupts the 
expression of the cytidine deaminase gene, resulting 
in defective class-switch recombination.\textsuperscript{3} Furthermore, 
\textit{NFkB1} deficiency can lead to defective B and T cells, 
generating hypogammaglobulinemia.\textsuperscript{5}

Emerging evidence suggests that \textit{NFkB1} mutations exhibit a more diverse phenotypic profile 
than previously thought, including autoinflammato-
ry episodes such as aphthae, febrile attacks, and
Recently, there have been increasing reports of concurrent CVID and PG linked to \( \text{NF} \kappa \text{B1} \) mutations. To our knowledge, there are 3 such cases in the literature. All 3 patients were middle-aged or elderly at PG onset; 2 individuals developed PG that resolved with intravenous immunoglobulin, while the other developed PG of unclear severity that did not respond to etanercept.

Several studies have elucidated the relevance of NF-\( \kappa \)B signaling in PG development. For instance, wild type NF-\( \kappa \)B protein regulates the nucleotide-binding leucine-rich repeat (NLR) family pyrin domain containing 3 (NLRP3) inflammasome, and a loss of regulation results in hyperactivation of this inflammasome, the mechanism underlying many autoinflammatory diseases. Some \( \text{NF} \kappa \text{B1} \) mutations deplete both p50 and p105, resulting in excessive Interleukin 1 beta secretion, inflammasome activation, and extreme pathergy-like responses (familial autoinflammatory necrotizing fasciitis) to minor trauma. Additionally, \( \text{NF} \kappa \text{B1} \)-deficient mice demonstrate enhanced neutrophil recruitment, which may also drive the hyperinflammation seen in PG.

Our case is unique because this is the first reported patient with a novel \( \text{NF} \kappa \text{B1} \) mutation who developed severe, recurrent PG episodes with coexisting immunodeficiency at a young age. In contrast to prior reports, our \( \text{NF} \kappa \text{B1} \) variant is located 2 base pairs 5’ to the end of exon 21, with \textit{in silico} analysis predicting complete obliteration of normal splicing. Unidentified modifier genes and environmental exposures may explain the variable penetrance and expressivity, as the father remains unaffected without CVID, recurrent and chronic infections or PG. We were unable to perform maternal sequencing. Our case expands the phenotypic landscape of \( \text{NF} \kappa \text{B1} \) mutations to include severe, recurrent PG at a young age and further supports the association between NF-\( \kappa \)B pathway dysregulation and CVID and PG pathogenesis.

We would like to thank the Yale Center for Mendelian Genomics for their assistance in genetic analysis.

**Conflicts of interest**

None disclosed.

**REFERENCES**

1. Bergler-Czop B, Brzezińska-Wcislo L. Pyoderma gangrenosum in a patient with common variable primary immunodeficiency. Postepy Dermatol Alergol. 2013;30(3):188-191.
2. Ashchyan HJ, Butler DC, Nelson CA, et al. The association of age with clinical presentation and comorbidities of pyoderma gangrenosum. JAMA Dermatol. 2018;154(4):409-413.
3. Tuinjenburg P, Lango Allen H, Burns SO, et al. Loss-of-function nuclear factor \( \kappa \)B subunit 1 (\( \text{NF} \kappa \text{B1} \)) variants are the most common monogenic cause of common variable immunodeficiency in Europeans. J Allergy Clin Immunol. 2018;142(4):1285-1296.
4. DeFilippis EM, Feldman SR, Huang WW. The genetics of pyoderma gangrenosum and implications for treatment: a systematic review. Br J Dermatol. 2015;172(6):1487-1497.
5. Kaustio M, Haapaniemi E, Göös H, et al. Damaging heterozygous mutations in \( \text{NF} \kappa \text{B1} \) lead to diverse immunologic phenotypes. J Allergy Clin Immunol. 2017;140(3):782-796.
6. Fliegauf M, Bryant VL, Frede N, et al. Haploinsufficiency of the NF-\( \kappa \)B1 subunit p50 in common variable immunodeficiency. J Hum Genet. 2015;97(3):389-403.
7. Fang R, Wang J, Jiang XY, Wang SH, Cheng H, Zhou Q. Case report: a novel mutation in \( \text{NF} \kappa \text{B1} \) associated with pyoderma gangrenosum. Front Genet. 2021;12:673453.
8. Kaustio M, Hautala T, Seppänen MRJ. Primary immunodeficiency, a possible cause of neutrophilic necrotizing dermatosis. JAMA Dermatol. 2019;155(7):863-864.
9. Oakley F, Mann J, Naird S, et al. Nuclear factor-kappaB1 (p50) limits the inflammatory and fibrogenic responses to chronic injury. Am J Pathol. 2005;166(3):695-708.
10. Wilson CL, Jurk D, Fullard N, et al. NF-\( \kappa \)B1 is a suppressor of neutrophil-driven hepatocellular carcinoma. Nat Commun. 2015;6(1):6818.